Pharmacological Characterization of Compounds Containing the Pyrimidinone Ring on ? 1-Adrenergic Receptors in Aorta Of Rats

  • Autor
  • Silvia Maria Luna Alves
  • Co-autores
  • Sidiane Barros da Silva , Wellington Francisco Pereira da Silva , Ruth Cristina Albuquerque dos Santos , Janaína Versiani dos Anjos , Alice Valença Araújo
  • Resumo
  •  

    Systemic Arterial Hypertension is an important public health problem and despite advances in antihypertensive therapy, most of the hypertensive individuals do not achieve adequate blood pressure levels. Pyrimidinone ring compounds may becandidates for antihypertensive drugs, since they antagonize ?1-adrenergic receptors, a targetfor antihypertensive drugs, such as prazosin. The aim of this study was to characterize the effects of SPRM09 e SPRM12, pyrimidinone ring compounds, on ?1-adrenergic receptors in rat aortas. Aortic rings with or without endothelium from Wistar rats (2-3 months) were mounted in an organ bath and their responses were recorded in an acquisition system. The cumulative concentration-effect curves for phenylephrine were constructed in the absence or in the presence of SPRM09 or SPRM12 (0.1 mmol/L). This study was approved by CEUA-UFPE (021446/2013-12). SPRM09 and SPRM12 reduced phenylephrine Emax only in aortas with endothelium (Control: Emax = 1.71±0.22g; pD2 = 7.45 ± 0.23, n = 7; + SPRM09: Emax = 1.13±0.18g; pD2 = 7.32 ± 0.32, n = 7, p <0.05; Control: Emax = 1.97±0.18g; pD2 = 7.4±0.20, n = 7; + SPRM12: Emax = 1.29±0.20 g; pD2 = 6.86±0.16, n = 7), but not in those without endothelium (Control: Control max = 2.27±0.16g; pD2 = 7.67 ± 0.65, n = 7; + SPRM09: Emax = 2.18±0.23g; pD2 = 7.93±0.35, n = 7, p> 0.05; + SPRM12: Emax = 2.08±0.20 g; pD2 = 7.62±0.19, n = 6). It is then suggested that the compounds are not antagonists of ?1-adrenergic receptors, but they may be ?2-adrenergic agonists.

     

  • Palavras-chave
  • Hypertension, receptors, alpha-adrenergic
  • Modalidade
  • Pôster
  • Área Temática
  • Sinalização celular
Voltar
  • Estresse oxidativo
  • Disfunção endotelial
  • Produtos naturais
  • Inflamação e doenças vasculares
  • Sinalização celular
  • Tecido adiposo perivascular
  • Sistema endócrino e doenças vasculares
  • Revisões, projetos, revisões sistemáticas e metanálises em biologia vascular
  • Educação em saúde e doenças vasculares
  • COVID-19 e complicações vasculares

Comissão Organizadora

José Wilson do Nascimento Corrêa
Simone Potje
Gabriel Tavares do Vale
Stêfany Cau
Roger Lyrio
Simone R Potje
Alice Valença Araújo
Ruth Cristina Albuquerque Santos
Lara Caroline Amaro
Ana Dária Cassoli da Silva
Pollyana Peixoto
Izabela Moreira Bonfim
Jocimar José Pitol
Sunamita Vaz Martins
Izabela Moreira Bonfim
Palloma Emanuelle Dornelas de Melo
Daniella Bonaventura
Tagana Rosa
Sarah Victory Santana Gomes
Priscila Cruz
André Lucas Borges
Jéssyca Aparecida Soares Giesen
Leticia Tinoco Gonçalves
Silvia Maria Luna Alves
NAYANA YARED BATISTA
Wellington Francisco Pereira da Silva
Natália Ferreira de Araújo
Leandro de Carvalho Gomes

Comissão Científica